« Previous
Next »
Transplantation Proceedings
Volume 39, Issue 3
, Pages 594-595
, April 2007
Case Report of a Kidney Transplant Recipient Converted to Everolimus Due to Malignancy: Resolution of Bronchiolitis Obliterans Organizing Pneumonia Without Everolimus Discontinuation
References
- Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004;66:383
- . Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol. 2005;56:71
- Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581
- Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1517
- . The role of human papillomavirus in gynecological diseases. Crit Rev Clin Lab Sci. 2000;37:183
- Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165
- . Future directions in the treatment of hormone sensitive advanced breast cancer: the RAD 001 (everolimus)-letrozole clinical program. Semin Oncol. 2006;33:S18
- Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope. 2006;116:814
- Sirolimus conversion for patients with Kaposi sarcoma. Am J Transplant. 2006;6:2164
- Sirolimus induced pneumonitis: three cases and a review of the literature. Am J Transplant. 2004;4:137
PII: S0041-1345(06)01570-3
doi: 10.1016/j.transproceed.2006.12.023
© 2007 Elsevier Inc. All rights reserved.
« Previous
Next »
Transplantation Proceedings
Volume 39, Issue 3
, Pages 594-595
, April 2007
